Treatment of osteoporosis

Clinical Obstetrics and Gynecology

Volumn 47, Issue 2, 2004, Pages 413-423

  Kleerekoper, Michael ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Endocrine Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; FLUORIDE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGUS INJURY; EXERCISE; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HYPERCALCEMIA; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; REVIEW; VENOUS THROMBOEMBOLISM;

CALCIUM, DIETARY; DIPHOSPHONATES; EXERCISE; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VITAMIN D;

EID: 3042770915     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200406000-00017     Document Type: Review

References (31)

1. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991;90:107-110.
2. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17:1-36. Available at: http://consensus.nih.gov/cons/111/111_statement.htm
3. Wehrli FW, Saha PK, Gomberg BR, et al. Role of magnetic resonance for assessing structure and function of trabecular bone. Top Magn Reson Imaging. 2002;13:335-355.
4. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-528.
5. WHO Study Group. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. WHO Technical Report Series 843. Geneva, Switzerland; 1994.
6. Black DM, Cummings SR, Melton LJ 3rd. Appendicular bone mineral and a woman's lifetime risk of hip fracture. J Bone Miner Res. 1992;7:639-646.
7. Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom. 1999;2:343-350.
8. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815-2822.
9. Miller PD, Siris ES, Barrett-Connor E, et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res. 2002;17:2222-2230.
10. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:1526-1536.
11. Looker AC, Bauer DC, Chesnut CH 3rd, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000;11:467-480.
12. Luukinen H, Kakonen SM, Pettersson K, et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res. 2000;15:2473-2478.
13. Delmas PD, Eastell R, Garnero P, et al. Committee of Scientific Advisors of the International Osteoporosis Foundation]. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11(suppl 6):S2-17.
14. Melton LJ 3rd, Crowson CS, O'Fallon WM, et al. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res. 2003;18:312-318.
15. Bruyere O, Collette J, Delmas P, et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas. 2003;44:259-265.
16. Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc. 2003;9:10-15.
17. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:1526-1536.
18. Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int. 2001;12:922-930.
19. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
20. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056.
21. Jilka RL. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone. 1998;23:75-81.
22. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97-106.
23. Cranney A, Tugwell P, Wells G, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev. 2002;23:496-507.
24. Cranney A, Wells G, Willan A, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-516.
25. Cranney A, Tugwell P, Adachi J, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:517-523.
26. Cranney A, Tugwell P, Zytaruk N, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies or postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:524-528.
27. Wells G, Tugwell P, Shea B, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-539.
28. Cranney A, Tugwell P, Zytaruk N, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:540-551.
29. Shea B, Wells G, Cranney A, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev. 2002;23:552-559.
30. Papadimitropoulos E, Wells G, Shea B, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of Vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23:560-569.
31. Cranney A, Guyatt G, Griffith L, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-578.